Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Capital Hilton

28 oct 2024 8:30 a.m. - 30 oct 2024 12:40 p.m.

1001 16th Street NW, Washington, DC 20036-5794

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 8: Hot Topics

Session Chair(s)

Emily  Place, PhD, MPH

Emily Place, PhD, MPH

Senior Consultant

Aclairo Pharmaceutical Development Group, United States

Ronald  Wange, PhD

Ronald Wange, PhD

Associate Director for Pharm/Tox OND

FDA, United States

Session 8: Hot Topics

Speaker(s)

Robert  Bell, PhD

Presentation Title: Harnessing RNA Exon Editing to Rewrite the Underlying Causes of Genetic Diseases

Robert Bell, PhD

Ascidian, United States

CSO

Stefan  Lutz, PhD

siRNA Manufacturing with Engineered Enzymes

Stefan Lutz, PhD

Codexis, Inc. , United States

SVP, Head of Research

Ronald  Wange, PhD

Confusion Arising from a Shared Vocabulary: What does “Platform” Really Mean?

Ronald Wange, PhD

FDA, United States

Associate Director for Pharm/Tox OND

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.